Theravance Biopharma’s (TBPH) lead pipeline candidate is ampreloxetine, which is being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).Theravance has collaborated with Viatris (VTRS) for the commercialization of Yupelri, as a once-daily, nebulized treatment of chronic obstructive pulmonary disease (COPD) in the United States.Here are some reasons why investors should consider betting on Theravance stock.Good Rank and Rising E ...